RAS Genes

Amgen’s KRAS Inhibitor Sotorasib Effective in Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer, Cancer, Chemotherapy, Clinical Trials, Immunotherapies, KRAS G12C Mutations, Overall Response Rate (ORR), R&D, RAS Genes, Solid Tumors

Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).

October 6, 2020/by Andrew Humphreys